Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal ArticleDOI
Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.
Muthukaman Nagarajan,Andrew Morrell,Smitha Antony,Glenda Kohlhagen,Keli Agama,Yves Pommier,Patricia A. Ragazzon,Nichola C. Garbett,Jonathan B. Chaires,Melinda Hollingshead,Mark Cushman +10 more
TL;DR: The biological results for substituted compounds revealed a disagreement between the structure-activity relationships of monomeric indenoisoquinolines and bisindenoisOquinoline as Top1 inhibitors, but cytotoxicity was maintained for both series of compounds.
Journal ArticleDOI
Gene Expression Profiles of the NCI-60 Human Tumor Cell Lines Define Molecular Interaction Networks Governing Cell Migration Processes
Kurt W. Kohn,Barry R. Zeeberg,William C. Reinhold,Margot Sunshine,Augustin Luna,Yves Pommier +5 more
TL;DR: The premise that genes whose expression at the mRNA level is correlated over diverse cell lines are likely to function together in a network of molecular interactions is explored, and molecular interaction maps (MIMs) are assembled that depict networks governing 3 cell migration processes.
Journal ArticleDOI
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
Haatisha Jandu,Kristina Aluzaite,Louise Fogh,Sebastian Wingaard Thrane,Julie B. Noer,Joanna Proszek,Khoa Nguyen Do,Stine Ninel Hansen,Britt Damsgaard,Signe Lykke Nielsen,Magnus Stougaard,Birgitta R. Knudsen,José M.A. Moreira,Petra Hamerlik,Madhavsai K. Gajjar,Marcel Smid,John W.M. Martens,John A. Foekens,Yves Pommier,Nils Brünner,Anne-Sofie Schrohl,Jan Stenvang +21 more
TL;DR: Based on the preclinical results, the predictive value of the BCRP should be analyzed in breast cancer patients scheduled for irinotecan treatment and LMP400 should be tested in a clinical setting in Breast cancer patients with resistance to irinOTecan.
Journal ArticleDOI
Azatoxin derivatives with potent and selective action on topoisomerase II.
François Leteurtre,Dan L. Sackett,Jose S. Madalengoitia,Glenda Kohlhagen,Timothy Macdonald,Ernest Hamel,Kenneth D. Paull,Yves Pommier +7 more
TL;DR: The aim of this study was to design azatoxin derivatives that would act only on tubulin or on top2, and selective inhibition of tubulin was obtained with 4'-methylazatoxin that was found to bind to the colchicine site.
Journal ArticleDOI
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis
Simone A Baechler,Valentina M. Factor,I. Dalla Rosa,A. Ravji,D. Becker,Salim Khiati,L. M. Miller Jenkins,Martin Lang,Carole Sourbier,Carole Sourbier,Stephanie A. Michaels,Leonard M. Neckers,Hongzhi Zhang,Antonella Spinazzola,Shar-yin N. Huang,Jens U. Marquardt,Yves Pommier +16 more
TL;DR: The authors show that TOP1MT has a tumor promoting role in hepatocellular carcinoma by supporting mitochondrial translation and that its deficiency limits tumorigenicity.